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Caveats in BerEP4 staining to
differentiate basal and squamous cell
carcinoma
Background: Superficial skin biopsies of basal cell carcinoma (BCC)
represent some of the most common dermatopathology specimens.
Superficial shave biopsies containing partial samples of lesions with
squamatization present difficulties in distinguishing BCC from
squamous cell carcinoma (SCC). BerEP4 has been employed as
a dependable marker in differentiating between BCCs and SCCs.
Methods: We collected 12 cases of superficial biopsies of BCC with
centrally located cords and strands suggesting squamous differentiation
at the Yale Dermatopathology Laboratory over a 3-month period and
stained them with BerEP4.
Results: We found that all cases (12 out of 12) showed membranous
and cytoplasmic staining with BerEP4 in the obvious areas of basaloid
differentiation at the periphery of the tumors, while cords and strands
of enlarged cells with squamoid features in the center and surface of
the biopsy failed to label with BerEP4.
Conclusions: BerEP4 labeling is not reliable in superficial biopsies
of BCC with squamoid features. It is important to be aware of this
caveat in interpreting BerEP4 staining for BCC and SCC.
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Superficial biopsies of basal cell carcinoma (BCC)
represent some of the most common skin specimens
received in pathology laboratories. With adequate
biopsies, diagnosis is usually straightforward, based
on peripheral palisading of basaloid nuclei, with cleft
artifact between tumor islands and a specialized
stroma. In some cases, however, superficial shave
biopsies containing partial samples of lesions present
difficulties in distinguishing BCC from squamous cell
carcinoma (SCC), especially when only the surface of
the lesion is visualized, and shows squamatization.
This phenomenon seems most prevalent in small
biopsies of ulcerated BCCs, in which the more
obvious basaloid features expected at the periphery
of the tumor are not contained in the biopsy. In such
cases, small cords and strands of enlarged pale cells
without basaloid features sometimes predominate.
Moreover, this caveat seems under-recognized in
major dermatopathology textbooks.1–3
In recent years, anti-human epithelial antigen
(BerEP4) has been widely used as a reliable marker
for BCC. Published data suggest that BerEP4 is
a dependable marker in differentiating BCC from
other neoplasms, most notably SCC, but also
including actinic keratosis and microcystic adnexal
carcinoma (MAC).4–7 In this study, we evaluated
BerEP4 labeling in cases of BCCs with superficial
squamous differentiation to evaluate its accuracy and
reliability in distinguishing such cases from superficial
samples of SCC.
Materials and methods
Twelve superficial biopsies of BCC with centrally
located cords and strands suggesting squamous
differentiationwere retrieved from the histopathology
archives at the Yale Dermatopathology Laboratory
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over a 3-month period. In addition, one case
diagnosed as SCC during the study period, and
identified as truly representing the surface of BCC on
re-excision, was also included.
Serial recut sections of all cases were labeled
BerEP4 monoclonal mouse anti-human antibody
(DakoCytomation GmbH) as the primary antibody,
at a concentration of 1:1000 with an incubation time
of 30 min, followed by a biotinylated secondary anti-
body for 15 min and streptavidin peroxidase conju-
gate for another 15 min. 3-Amino-9-ethylcarbazol
was used to visualize the end product.
Results
Twelve cases were included. See Table 1 for clinical
information. Twelve of 12 cases showedmembranous
and cytoplasmic staining with BerEP4 in the obvious
areas of basaloid differentiation at the peripheryof the
tumors, while uninvolved epidermis was not stained.
In each case, cords and strands of enlarged cells
without basaloid features in the center and surface of
the biopsy failed to label with BerEP4 (Fig. 1). In
a biopsy of BCC that was originally interpreted as
SCC prior to re-excision, the squamoid cords and
strands present in the biopsy were negative for
BerEP4. In contrast, the more clear-cut BCC on re-
excision was strongly positive for BerEP4.
Discussion
BerEP4 reacts with 34-kDa and 39-kDa glycoproteins
present on the cell surface and in the cytoplasm of
most human epithelial and carcinoma cells.8 In the
skin, BerEP4 stains normal adnexal epithelium,
including the apocrine and eccrine epithelium,
matrical and outer sheath epithelium of vellus anagen
follicles and inferior segment epithelium of vellus
telogen follicles.4,9 BerEP4 reacts with cutaneous
BCC, Merkel cell carcinoma, trichoepithelioma,
tumors with sweat duct differentiation and follicular
induction over dermatofibromas.4,6,10 The usefulness
of stainingwith BerEP4 to distinguish cutaneous BCC
from SCC has been well shown. In a series with 22
cases of BCCs and 21 cases of SCCs, Tellechea et al.4
showed diffuse and intense labeling of BerEP4 in all
BCCs, but no expression in any of SCCs. In another
study performed by Kist et al.,6 27 of 27 BCCs,
including nodular, morpheaform/infiltrative and
adenoid variants, were positive for BerEP4. BerEP4
defined areas of BCC in dense inflammation better
than hematoxylin and eosin (H&E) stain in 13 of 27
BCCs and identified the final Mohs margins in two
cases of infiltrative BCC that were otherwise appear-
ing negative with routine H&E stain. Our experience
of BerEP4 immunoreactivity in SCC is consistent
with the literature. All (5 of 5) SCCs retrieved from the
same period as BCCs in this study were negative for
BerEP4. It has also been shown that BerEP4 reliably
differentiatesMAC fromBCC to the same extent as it
distinguishes the latter tumor from SCC.5
BCCmay show areaswithmorphologically distinct
squamous cells, with or without keratinization. Those
areas are usually located in superficial papillary
dermis overlying more typical foci of palisaded
epithelium and can make it challenging to diagnose
BCC when only superficial biopsy is conducted. It is
important to note that the clinical impression was
SCC’ in several of our cases, potentially misleading
the pathologist in histologically ambiguous cases. To
the best of our knowledge, no study has been done to
evaluate BerEP4 expression in these cases. The data
in this study suggest that staining for BerEP4
differentiate between BCC and SCC in such
ambiguous cases is not reliable.
The terms basosquamous carcinoma’ and meta-
typical carcinoma’ are somewhat controversial and
confusingbut aremost often applied to carcinomaswith
contiguous areas of both BCC and SCC, usually with
less obvious peripheral palisading, and typically with an
aggressive clinical behavior. Some authors feel that
these tumors represent a transition between BCC and
SCC.2 Keratotic BCC also shows squamous differen-
tiation, typically in the form of keratin pearls and
differentiation toward hair follicles. However, these
features are usually located in the center of tumors, in
contradistinction to the pattern observed in this report
affecting the surface only and under areas of ulceration.
Some basosquamous carcinomas also exhibit epithelial
pearls. In one study, positive BerEP4 staining was
identified in all basosquamous carcinomas, while two of
the basosquamous carcinomas were negative for
BerEP4 in small foci that had well-developed epithelial
pearl formation.11
In summary, we commonly receive superficial
biopsies in which the precise classification of carci-
noma is problematic.While anattempt canbemade to
favor either BCC or SCC on histological grounds, this
Table 1. Clinical information
Case Age (years) Sex Site Clinical diagnosis Size (mm3)
1 70 F Left leg AK, BCC 5 3 5 3 2
2 50 M Left cheek SCC 4 3 3 3 1
3 79 M Forehead SCC 5 3 2 3 2
4 50 F Left chest BCC 6 3 5 3 1
5 71 F Nose BCC 5 3 4 3 1
6 53 M Nose BCC 5 3 5 3 1
7 59 M Face SCC 5 3 4 3 1
8 62 F Left leg SCC 2 3 2 3 2
9 78 M Left neck BCC 5 3 5 3 1
10 88 F Nose BCC 7 3 5 3 3
11 71 M Forehead SCC 5 3 4 3 1
12 61 F Nose BCC 8 3 6 3 1




is not completely reliable. We hoped, based on results
in the literature, that staining with BerEP4 would be
a useful adjunct in these cases. Unfortunately, despite
strong staining of the periphery of such BCCs with
BerEP4, staining with this antibody is consistently
negative in superficial areas of tumor showing a more
squamoid appearance. Awareness of this caveat in
BerEP4 staining for BCC and SCC is important.
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Fig. 1. BerEP4 labeled the obvious areas of basaloid differentiation at the periphery of superficial biopsies of basal cell carcinoma. Squamous
differentiation in the center and surface of the biopsies (indicated by arrows) failed to label with BerEP4. A and B) H&E and BerEP4 stains of
one biopsy (3400). C and D) H&E and BerEP4 stains of another biopsy (3400)
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